Clinical trials: Hypertension, Portal
- Condition Hypertension, Portal
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Erectile Dysfunction, Pulmonary Arterial Hypertension
Study of the Pharmacokinetics and Safety of TPN171H Tablets in Subjects With Mild ,Moderate Hepatic Insufficiency and Normal Liver Function
The study aims to investigate and compare the effect of TPN171H on subjects with mild and moderate hepatic impairment compared to healthy subjects.
- Trial name
- NCT05185011
- Testing
- TPN171H
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vigonvita Life Sciences
Essential Hypertension, Hepatic Impairment
A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Hepatic Impairment Patients and Healthy Volunteers
To compare and evaluate the pharmacokinetic characteristics and the safety of fimasartan in hepatic impairment patients and healthy volunteers
- Trial name
- NCT01146938
- Testing
- fimasartan
- Where
- South Korea
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Cirrhosis
Spleen Stiffness Measurement With FibroScan
FibroScan® (Echosens, Paris, France) is an active non implantable medical device marketed in Europe since December 2003 and is currently used in many countries.
- Trial name
- NCT02180113
- Testing
- Fibroscan® examination
- Where
- 7 sites in France, Italy and 2 more
- Volunteers
- 403 people, healthy volunteers welcome
- Sponsor
- Echosens
Hypertension
Phase 1 PK Study to Evaluate the PK of CIN-107 in Subjects With Hepatic Impairment
The goal of this Phase 1, open-label, single-dose, parallel-group study is to evaluate the pharmacokinetics (PK) of a single 10-mg oral dose of baxdrostat in subjects with varying degrees of hepatic function.
- Trial name
- NCT05961397
- Testing
- baxdrostat
- Where
- 5 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Symptomatic Neurogenic Orthostatic Hypertension, nOH
Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855
An open-label study to characterize the effects of mild, moderate, and severe Hepatic Impairment (HI) on the pharmacokinetics (PK) of ampreloxetine following a single oral dose in comparison with healthy volunteers with normal…
- Trial name
- NCT04200573
- Testing
- Ampreloxetine
- Where
- 2 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma